Published in Osteoporos Int on December 24, 2010
The Association Between Hyponatremia and Osteoporosis in Patients With Epilepsy. | NCT03371199
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int (2015) 2.15
Treatment failure in osteoporosis. Osteoporos Int (2012) 1.82
Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med (2014) 1.75
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet (2015) 1.57
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res (2016) 1.50
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int (2012) 1.36
Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab (2014) 1.35
Osteoporosis, fractures, and diabetes. Int J Endocrinol (2014) 1.34
Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol (2012) 1.25
Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int (2012) 1.25
The clinical utility of bone marker measurements in osteoporosis. J Transl Med (2013) 1.21
Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Ann Lab Med (2012) 1.17
Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One (2012) 1.14
Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. BMC Infect Dis (2012) 1.10
Treatment of osteoporosis in men. Bone (2012) 1.06
National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int (2012) 0.99
Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry (2012) 0.98
Cancer-associated bone disease. Osteoporos Int (2013) 0.94
Bisphosphonate drug holiday: choosing appropriate candidates. Curr Osteoporos Rep (2013) 0.93
Prevalence of vitamin D insufficiency and low bone mineral density in elderly Thai nursing home residents. BMC Geriatr (2012) 0.90
Reference intervals of bone turnover markers determined by using their curve-fitting valley for adult females in China. Osteoporos Int (2013) 0.88
Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis. Osteoporos Int (2013) 0.87
PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int (2014) 0.87
Higher bone turnover is related to spinal radiographic damage and low bone mineral density in ankylosing spondylitis patients with active disease: a cross-sectional analysis. PLoS One (2014) 0.86
The effect of three years of TNFα blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther (2012) 0.86
Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis. Osteoporos Int (2014) 0.85
Effect of chronic activity-based therapy on bone mineral density and bone turnover in persons with spinal cord injury. Eur J Appl Physiol (2013) 0.85
Are we taking full advantage of the growing number of pharmacological treatment options for osteoporosis? Curr Opin Pharmacol (2014) 0.85
Possible role of lymphocytes in glucocorticoid-induced increase in trabecular bone mineral density. J Endocrinol (2014) 0.84
Goal-directed treatment of osteoporosis in Europe. Osteoporos Int (2014) 0.84
Bone and the perimenopause. Obstet Gynecol Clin North Am (2011) 0.84
International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int (2017) 0.84
Evaluation of a topical herbal agent for the promotion of bone healing. Evid Based Complement Alternat Med (2015) 0.83
Comparing tolerability and efficacy of generic versus brand alendronate: a randomized clinical study in postmenopausal women with a recent fracture. PLoS One (2013) 0.83
Fructus Ligustri Lucidi (FLL) ethanol extract increases bone mineral density and improves bone properties in growing female rats. J Bone Miner Metab (2013) 0.81
Biochemical markers for bone turnover predict risk of vertebral fractures in postmenopausal women over 10 years: the Japanese Population-based Osteoporosis (JPOS) Cohort Study. Osteoporos Int (2012) 0.81
Identification of miR-194-5p as a potential biomarker for postmenopausal osteoporosis. PeerJ (2015) 0.81
Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide 20 μg/day administered subcutaneously in Japanese patients with osteoporosis. J Bone Miner Metab (2012) 0.81
A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. Clin Genitourin Cancer (2013) 0.80
Biochemical markers in the follow-up of the osteoporotic patients. Clin Cases Miner Bone Metab (2012) 0.80
Circulating sclerostin levels and markers of bone turnover in Chinese-American and white women. J Clin Endocrinol Metab (2013) 0.80
Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products. Nutr Res Rev (2014) 0.80
The association between critical illness and changes in bone turnover in adults: a systematic review. Osteoporos Int (2014) 0.80
Bone remodeling markers and bone metastases: From cancer research to clinical implications. Bonekey Rep (2015) 0.80
Chronic kidney disease and the skeleton. Bone Res (2014) 0.79
Reference intervals for serum osteocalcin concentrations in adult men and women from the study of health in Pomerania. BMC Endocr Disord (2013) 0.79
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study. Br J Cancer (2013) 0.79
Bone impairment assessed by HR-pQCT in juvenile-onset systemic lupus erythematosus. Osteoporos Int (2015) 0.79
Osteoporosis in the adult solid organ transplant population: underlying mechanisms and available treatment options. Osteoporos Int (2015) 0.78
Denosumab for treating periprosthetic osteolysis; study protocol for a randomized, double-blind, placebo-controlled trial. BMC Musculoskelet Disord (2016) 0.78
Potential Extensions of the US FRAX Algorithm. J Osteoporos (2012) 0.78
Expressions and clinical significance of serum bone Gla-protein, bone alkaline phosphatase and C-terminal telopeptide of type I collagen in bone metabolism of patients with osteoporosis. Pak J Med Sci (2015) 0.78
Bone turnover biomarkers and risk of osteoporotic hip fracture in an Asian population. Bone (2015) 0.78
Effect of high dietary sodium on bone turnover markers and urinary calcium excretion in Korean postmenopausal women with low bone mass. Eur J Clin Nutr (2015) 0.78
Harmonised Australian Reference Intervals for Serum PINP and CTX in Adults. Clin Biochem Rev (2014) 0.77
Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. J Endocrinol Invest (2016) 0.77
Bone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women's health practice. Int J Womens Health (2016) 0.77
The importance of assessing the rate of bone turnover and the balance between bone formation and bone resorption during daily teriparatide administration for osteoporosis: a pilot study. J Bone Miner Metab (2015) 0.77
A study of the link between bone turnover markers and bone mineral density with inflammation and body mass in postmenopausal women with active rheumatoid arthritis. J Bone Miner Metab (2012) 0.77
Zinc Supplementation Increases Procollagen Type 1 Amino-Terminal Propeptide in Premenarcheal Girls: A Randomized Controlled Trial. J Nutr (2015) 0.77
The relationship of thoracic kyphosis to gait performance and quality of life in women with osteoporosis. Osteoporos Int (2015) 0.76
Bone turnover markers predict hip bone loss in elderly European men: results of the European Male Ageing Study (EMAS). Osteoporos Int (2014) 0.76
Study of the distribution by age group of serum cross-linked C-terminal telopeptide of type I collagen and procollagen type I N-propeptide in healthy Japanese women to establish reference values. J Bone Miner Metab (2013) 0.76
Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). Osteoporos Int (2011) 0.76
The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club. Osteoporos Int (2016) 0.76
Teriparatide for osteoporosis: importance of the full course. Osteoporos Int (2016) 0.75
How can gynaecologists cope with the silent killer - osteoporosis? Prz Menopauzalny (2017) 0.75
An overview and management of osteoporosis. Eur J Rheumatol (2016) 0.75
Transcriptional landscape analysis identifies differently expressed genes involved in follicle-stimulating hormone induced postmenopausal osteoporosis. Exp Biol Med (Maywood) (2016) 0.75
Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy. Curr Osteoporos Rep (2012) 0.75
Evaluation of Bone Metabolism in Critically Ill Patients Using CTx and PINP. Biomed Res Int (2016) 0.75
Urinary N-telopeptide and Rate of Bone Loss Over the Menopause Transition and Early Postmenopause. J Bone Miner Res (2016) 0.75
Dried Plums, Prunes and Bone Health: A Comprehensive Review. Nutrients (2017) 0.75
Serum 25-hydroxyvitamin D and bone turnover markers in Palestinian postmenopausal osteoporosis and normal women. Arch Osteoporos (2017) 0.75
Qianggu capsule for the treatment of primary osteoporosis: evidence from a Chinese patent medicine. BMC Complement Altern Med (2017) 0.75
Reduced bone formation markers, and altered trabecular and cortical bone mineral densities of non-paretic femurs observed in rats with ischemic stroke: A randomized controlled pilot study. PLoS One (2017) 0.75
Bone effects of rosiglitazone in HIV-infected patients with lipoatrophy. HIV Clin Trials (2012) 0.75
Bone health status in Indian women. Indian J Med Res (2013) 0.75
Bone turnover markers: Emerging tool in the management of osteoporosis. Indian J Endocrinol Metab (2016) 0.75
Elevated Bone Turnover Markers after Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Breast and Ovarian Cancer. PLoS One (2017) 0.75
Effect of vitamin D3-supplementation on bone markers (serum P1NP and CTX): A randomized, double blinded, placebo controlled trial among healthy immigrants living in Norway. Bone Rep (2015) 0.75
Diagnostic performance of osteocalcin measurements in patients with endogenous Cushing's syndrome. Bonekey Rep (2016) 0.75
Measurement of β-isomerized C-terminal telopeptide of type I collagen in patients with POEMS syndrome: diagnostic, prognostic, and follow-up utilities. Blood Cancer J (2016) 0.75
Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial. Osteoporos Int (2015) 0.75
Collaborating with International Clinical Organizations. EJIFCC (2015) 0.75
Battle of the sex steroids in the male skeleton: and the winner is…. J Clin Invest (2016) 0.75
Intermittent Nitrate Use and Risk of Hip Fracture. Am J Med (2016) 0.75
High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurol (2017) 0.75
Safety and efficacy of tocotrienol supplementation for bone health in postmenopausal women: protocol for a dose-response double-blinded placebo-controlled randomised trial. BMJ Open (2016) 0.75
Assessment of vitamin D status and serum CrossLaps levels in adults with primary lactose malabsorption. Eur J Clin Nutr (2016) 0.75
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards: osteoporos int 2011;22:391-420. Clin Biochem Rev (2011) 0.75
Intact Telopeptides Enhance Interactions between Collagens. Biophys J (2016) 0.75
The utility of procollagen type 1 N-terminal propeptide for the bone status assessment in postmenopausal women. Bosn J Basic Med Sci (2013) 0.75
Response of bone turnover markers to raloxifene treatment in postmenopausal women with osteopenia. Osteoporos Int (2016) 0.75
Bone mineral density in people living with HIV: a narrative review of the literature. AIDS Res Ther (2017) 0.75
Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons. Eur J Nucl Med Mol Imaging (2016) 0.75
Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club. Calcif Tissue Int (2017) 0.75
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res (2007) 14.84
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
The diagnosis of osteoporosis. J Bone Miner Res (1994) 10.90
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
Statistical validation of intermediate endpoints for chronic diseases. Stat Med (1992) 7.44
Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med (2007) 7.38
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med (1993) 6.08
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc (2006) 5.32
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab (1998) 4.28
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med (2005) 4.03
IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem (2004) 4.02
A reference standard for the description of osteoporosis. Bone (2007) 3.67
Treatment of postmenopausal osteoporosis. Lancet (2002) 3.37
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med (2000) 3.16
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res (2002) 3.15
Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med (2002) 3.10
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Prediction of rapid bone loss in postmenopausal women. Lancet (1987) 2.76
Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas (2009) 2.74
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res (2007) 2.68
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med (2007) 2.64
Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res (1996) 2.61
Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res (1996) 2.59
Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone (2004) 2.48
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab (2008) 2.43
Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab (1994) 2.39
Dietary calcium, physical activity, and risk of hip fracture: a prospective study. BMJ (1989) 2.24
Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res (2000) 2.24
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res (2004) 2.23
Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab (2002) 2.15
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res (2007) 2.15
The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int (2000) 2.14
Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int (2004) 2.11
Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab (1997) 2.04
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res (2003) 1.96
Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res (2010) 1.95
Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium, and the United States. J Bone Miner Res (2009) 1.89
Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res (2004) 1.87
Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem (2009) 1.85
Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res (1998) 1.85
Interlaboratory variation of biochemical markers of bone turnover. Clin Chem (2001) 1.82
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res (2005) 1.81
Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest (1993) 1.78
Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int (2008) 1.77
Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res (2004) 1.76
A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int (2002) 1.70
The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab (2004) 1.69
Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res (2005) 1.68
The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab (1997) 1.66
Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med (1997) 1.63
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom (2004) 1.59
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res (2005) 1.57
Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res (2005) 1.56
The degree of mineralization is a determinant of bone strength: a study on human calcanei. Bone (2004) 1.54
Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int (2008) 1.50
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int (2004) 1.48
Mechanical properties of adult vertebral cancellous bone: correlation with collagen intermolecular cross-links. J Bone Miner Res (2002) 1.46
Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone (1996) 1.45
Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporos Int (2009) 1.44
Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab (2007) 1.43
Potential risk factors for development of postmenopausal osteoporosis--examined over a 12-year period. Osteoporos Int (1991) 1.42
Report of the IFCC Working Group for Standardization of Thyroid Function Tests; part 1: thyroid-stimulating hormone. Clin Chem (2010) 1.41
Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int (2009) 1.37
Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int (2000) 1.36
Traceability, reference systems and result comparability. Clin Biochem Rev (2007) 1.33
Implementation of reference systems in laboratory medicine. Clin Chem (2000) 1.33
Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res (1998) 1.32
Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone (2009) 1.26
A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med (2001) 1.25
Mean wall thickness and formation periods of trabecular bone packets in idiopathic osteoporosis. Calcif Tissue Int (1981) 1.21
Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int (2001) 1.20
An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol (2006) 1.20
Relative contributions of bone density, bone turnover, and clinical risk factors to long-term fracture prediction. J Bone Miner Res (2003) 1.20
FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int (2009) 1.19
Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int (2002) 1.19
Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res (2003) 1.17
Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res (2003) 1.16
Bone resorption and osteoporotic fractures in elderly men: the dubbo osteoporosis epidemiology study. J Bone Miner Res (2004) 1.16
Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res (2005) 1.16
Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone (2004) 1.14
A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone (2007) 1.13
Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study. J Bone Miner Res (2009) 1.13
Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem (2007) 1.13
Toward standardization of cardiac troponin I measurements part II: assessing commutability of candidate reference materials and harmonization of cardiac troponin I assays. Clin Chem (2006) 1.12
Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone (1987) 1.09
Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis Study. Osteoporos Int (2010) 1.09
Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J Bone Miner Res (2000) 1.09
Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int (2000) 1.09
Establishing a reference range for bone turnover markers in young, healthy women. Bone (2008) 1.09
Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract (2009) 1.06
Risk factors for vertebral and nonvertebral fracture over 10 years: a population-based study in women. J Bone Miner Res (2008) 1.06
Predictors of fractures in elderly women. Osteoporos Int (2000) 1.06
Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study. BMJ (1996) 1.05
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (1987) 24.27
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int (2006) 11.05
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
World-wide projections for hip fracture. Osteoporos Int (1997) 6.83
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
Risk of new vertebral fracture in the year following a fracture. JAMA (2001) 6.17
Epidemiology of fractures in England and Wales. Bone (2001) 5.76
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int (2005) 5.54
Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int (2009) 5.43
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
Perspective. How many women have osteoporosis? J Bone Miner Res (1992) 4.99
Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study. Lancet (2006) 4.95
A meta-analysis of previous fracture and subsequent fracture risk. Bone (2004) 4.92
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int (2000) 4.85
Radiographic patterns of osteoarthritis of the knee joint in the community: the importance of the patellofemoral joint. Ann Rheum Dis (1992) 4.79
Use of oral corticosteroids and risk of fractures. J Bone Miner Res (2000) 4.75
Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer (1984) 4.46
EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis (2000) 4.37
An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int (2004) 4.24
Bone density screening for osteoporosis. Lancet (1990) 3.87
Defining osteoarthritis of the hip for epidemiologic studies. Am J Epidemiol (1990) 3.77
Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int (2009) 3.74
Mortality after osteoporotic fractures. Osteoporos Int (2003) 3.68
A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int (2012) 3.62
Cohort profile: the Hertfordshire cohort study. Int J Epidemiol (2005) 3.62
Bone densitometry in clinical practice. BMJ (1995) 3.48
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int (2002) 3.45
Complete genomic sequence and analysis of the prion protein gene region from three mammalian species. Genome Res (1998) 3.44
The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res (1996) 3.25
Determinants of disability in osteoarthritis of the knee. Ann Rheum Dis (1993) 3.16
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med (2000) 3.16
Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2002) 3.16
Fluoride in drinking water and risk of hip fracture in the UK: a case-control study. Lancet (2000) 3.16
Knee pain and disability in the community. Br J Rheumatol (1992) 3.15
Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study. Osteoporos Int (2012) 3.13
Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int (2011) 3.04
Pectin esterification is spatially regulated both within cell walls and between developing tissues of root apices. Planta (1990) 3.03
Milk intake and bone mineral acquisition in adolescent girls: randomised, controlled intervention trial. BMJ (1997) 3.01
GP job satisfaction in 1987, 1990 and 1998: lessons for the future? Fam Pract (2000) 2.99
Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest (2000) 2.94
Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum (2003) 2.94
Maternal vitamin D status during pregnancy and child outcomes. Eur J Clin Nutr (2007) 2.94
Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int (2002) 2.82
Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int (2012) 2.81
Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford) (2007) 2.81
Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int (1997) 2.80
Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol (1996) 2.76
Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas (2009) 2.74
Back pain in Britain: comparison of two prevalence surveys at an interval of 10 years. BMJ (2000) 2.73
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int (1999) 2.70
Proliferative verrucous leukoplakia. A long-term study of thirty patients. Oral Surg Oral Med Oral Pathol (1985) 2.70
A global representation of vitamin D status in healthy populations. Arch Osteoporos (2012) 2.69
Osteoarthritis of the hip: an occupational disease in farmers. BMJ (1992) 2.69
The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int (1993) 2.66
Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res (2000) 2.55
Occupational physical activities and osteoarthritis of the knee. Arthritis Rheum (2000) 2.54
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol (1993) 2.50
Manual handling activities and risk of low back pain in nurses. Occup Environ Med (1995) 2.48
Impact of nutrition on muscle mass, strength, and performance in older adults. Osteoporos Int (2012) 2.48
Use of statins and risk of fractures. JAMA (2001) 2.47
Prospective cohort study of predictors of incident low back pain in nurses. BMJ (1997) 2.46
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med (1998) 2.42
Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J Bone Miner Res (1990) 2.39
Recommendations for standardization and phenotype definitions in genetic studies of osteoarthritis: the TREAT-OA consortium. Osteoarthritis Cartilage (2010) 2.39
Bone-density measurement. Lancet (1992) 2.38
Trends in admissions for hip fracture in England and Wales, 1968-85. BMJ (1990) 2.35
ABC of rheumatology. Osteoporosis. BMJ (1995) 2.33
Knee osteoarthritis and obesity. Int J Obes Relat Metab Disord (2001) 2.30
Late effects of radiation therapy in the head and neck region. Int J Radiat Oncol Biol Phys (1995) 2.28
Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum (2006) 2.28
How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the general practice research database? Arthritis Rheum (2008) 2.27
Risk of fractures in patients with multiple sclerosis: a population-based cohort study. Neurology (2012) 2.25
Vertebral fractures predict subsequent fractures. Osteoporos Int (1999) 2.24
Dietary calcium, physical activity, and risk of hip fracture: a prospective study. BMJ (1989) 2.24
A multicentre randomized controlled trial of epidural corticosteroid injections for sciatica: the WEST study. Rheumatology (Oxford) (2005) 2.23
Acetabular dysplasia and hip osteoarthritis in Britain and Japan. Br J Rheumatol (1998) 2.22
The nucleotide sequence of a cloned Drosophila arginine tRNA gene and its in vitro transcription in Xenopus germinal vesicle extracts. J Biol Chem (1979) 2.21
Fracture risk following an osteoporotic fracture. Osteoporos Int (2003) 2.21
Bacterial arthritis in an English health district: a 10 year review. Ann Rheum Dis (1986) 2.21
Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int (1999) 2.20
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer (2011) 2.20
Male circumcision for the prevention of heterosexually acquired HIV infection: a meta-analysis of randomized trials involving 11,050 men. HIV Med (2008) 2.19